DDrare: Database of Drug Development for Rare Diseases

226. 間質性膀胱炎（ハンナ型）
［臨床試験数：133，薬物数：151（DrugBank：46），標的遺伝子数：48，標的パスウェイ数：137］

Searched query = "Interstitial cystitis with Hunners ulcer", "Interstitial cystitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2% sodium chondroitin sulfate; 5% lidocaine/5 mg/ml 0.02% estradiol compound cream; AGN 203818; AQX-1125; AQX-1125 100 mg; AQX-1125 200 mg; ASP3652; ASP6294; Adalimumab; Alkalinized Lidocaine-Heparin; Amitriptyline; BOTOX 200U in normal saline; Bladder Instillations; Bladder instillation WITH triamcinolone acetonide; Bladder instillation WITHOUT triamcinolone acetonide; Bladder instillation with heparin/ lidocaine; Botox; Botulinum toxin A; Buckwheat; Bupivacaine; CICLOSPORIN; Cannabidiol; Cannabidiol vaginal suppository; Capsaicin; Certolizumab pegol; Chondroitin sulfate; Ciclosporin; Ciklosporin; Combination Product: Hyperbaric Oxygen Therapy-; Cyclosporine; DMSO; DMSO cocktail; Device: Intermittent Exposure to Oxygen via Oro-Nasal Mask; Device: interferential current; Dexmedetomidine; Dimethyl sulfoxide; ERB-041; Estradiol; Fospropofol; Fospropofol (Lusedra®) 10; Fospropofol (Lusedra®) 12; Fospropofol (Lusedra®) 6.5; Fremanezumab; Gefapixant; Glycine; Gralise; Heparin; Heparin & Alkalinized Lidocaine Bladder Instillation; Hyaluronic Acid and Chondroitin Sulfate; Hyaluronic acid; Hyaluronic acid/chondroitin sulfate; Hydrogen; IC Cocktail; IPD® (Japanese tradename); IPD® (suplatast tosilate); Intravesical onabotulinumtoxinA injection; JNJ-42160443; KRP-116D; Ketorolac; Ketorolac Tromethamine; LP-08 20mg; LP-08 80mg; LiRIS 400 mg; LiRIS low dose and LiRIS high dose; LiRIS®; LiRIS® 400 mg; Lidocaine; Lidocaine Releasing Intravesical System - LiRIS®; Liposome encapsulated BoNT-A; Liposomes; Low-dose naltrexone; MMF; MN-001; MN-001 BID; MR-MC-01; Metoprolol; Metoprolol Tartrate Oral Tablet; Mirabegron; Mycofenolate Mofetil (MMF); Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofetil; NALOXONE HYDROCHLORIDE; Naloxone; Naltrexone; Normal Saline; Normal saline; Normal saline instillation; Nortriptyline; OXN 10/5 mg PR; OXN 20/10 mg PR; OXN 5/2.5 mg PR; OXYCODONE HYDROCHLORIDE; Omalizumab; Onabotulinum Toxin A; Onabotulinumtoxin A; OnabotulinumtoxinA; Other: Hyperbaric Oxygen Therapy; Other: Normal Saline; Other: Saline as a nasal spray; Other: inactive drug; Other: normal saline; Oxycodone; Oxycodone naloxone prolonged release tablets; Oxycodone/naloxone prolonged release t; Oxycodone/naloxone prolonged release tablets 10/5 mg; Oxycodone/naloxone prolonged release tablets 20/10 mg; Oxycodone/naloxone prolonged release tablets 5/2.5 mg; Oxygen; Oxytocin; PD 0299685; PD 0299685 at 15mg BID; PD 0299685 at 30mg BID; PD-0299685; PF-04383119; Pentosan polysulfate; Pentosan polysulfate sodium 100 mg; Placebo; Platelet enriched plasma; Platelet-Rich Plasma; Procedure: Pelvic Floor Physical Therapy; Procedure: Sham Cystoscopy Procedure; Procedure: Urodynamic study; Procedure: injections on posterior bladder wall excluding the trigone; Procedure: injections upper aspect of trigone of urinary bladder; Prograf; Propiverine; Propiverine Hydrochloride; RIMSO 50; RN624, RI624; Rimso 50; SANDIMMUN; SI-722; Sandimmun Neoral; Sildenafil; Sulfate; Suplatast tosilate; TACROLIMUS; TTI-1612; Tacrolimus; Tanezumab; Targinact 10 mg/5 mg prolonged-release tablets; Targinact 20mg/10 mg prolonged-release tablets; Targinact 5mg/2.5 mg prolonged-release tablets; Tramadol; Triamcinolone; Tromethamine; URG101; Water; YM672; YM672 (IPD®)

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-004138-12-BE (EUCTR)	27/11/2017	19/07/2017	Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.	A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis	Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]		Astellas Pharma Europe B.V.	NULL	Not Recruiting			Female: yes Male: no	163	Phase 2	Hungary;Czech Republic;Poland;Spain;Belgium;Russian Federation;Netherlands;Latvia;Germany;United Kingdom
2	EUCTR2016-004138-12-GB (EUCTR)	30/10/2017	17/07/2017	Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.	A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis	Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]		Astellas Pharma Europe B.V.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: no	163	Phase 2	Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom
3	EUCTR2016-004138-12-NL (EUCTR)	23/10/2017	24/07/2017	Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.	A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis	Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]		Astellas Pharma Europe B.V.	NULL	Not Recruiting			Female: yes Male: no	163	Phase 2	Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Latvia;Germany;Netherlands;United Kingdom
4	NCT03282318 (ClinicalTrials.gov)	September 28, 2017	12/9/2017	A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis	A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis	Bladder Pain Syndrome;Interstitial Cystitis	Drug: ASP6294;Drug: Placebo	Astellas Pharma Europe B.V.	NULL	Completed	18 Years	N/A	Female	119	Phase 2	Belgium;Czechia;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom
5	EUCTR2016-004138-12-PL (EUCTR)	27/09/2017	19/07/2017	Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.	A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis	Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]	Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294	Astellas Pharma Europe B.V.	NULL	Not Recruiting			Female: yes Male: no	163	Phase 2	Hungary;Czech Republic;Belgium;Spain;Poland;Russian Federation;Netherlands;Latvia;Germany;United Kingdom
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	EUCTR2016-004138-12-DE (EUCTR)	26/09/2017	10/07/2017	Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.	A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis	Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]		Astellas Pharma Europe B.V.	NULL	Not Recruiting			Female: yes Male: no	163	Phase 2	Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom
7	EUCTR2016-004138-12-ES (EUCTR)	18/09/2017	18/09/2017	Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.	A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis	Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]	Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294	Astellas Pharma Europe B.V.	NULL	Not Recruiting			Female: yes Male: no	163	Phase 2	Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom
8	EUCTR2016-004138-12-HU (EUCTR)	14/09/2017	12/07/2017	Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.	A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis	Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]	Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294	Astellas Pharma Europe B.V.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: no	163	Phase 2	Czech Republic;Hungary;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom
9	EUCTR2016-004138-12-CZ (EUCTR)	30/08/2017	13/07/2017	Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.	A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis	Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]	Product Name: ASP6294 INN or Proposed INN: Not applicable Other descriptive name: ASP6294	Astellas Pharma Europe B.V.	NULL	Not Recruiting			Female: yes Male: no	163	Phase 2	Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom
10	EUCTR2016-004138-12-LV (EUCTR)	04/08/2017	25/07/2017	Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.	A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis	Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC) MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]		Astellas Pharma Europe B.V.	NULL	Not Recruiting			Female: yes Male: no	163	Phase 2	Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Germany;Latvia;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2016-004138-12-BE
(EUCTR)

27/11/2017

19/07/2017

Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis

Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC)
MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]

Astellas Pharma Europe B.V.

NULL

Not Recruiting

Female: yes
Male: no

163

Phase 2

Hungary;Czech Republic;Poland;Spain;Belgium;Russian Federation;Netherlands;Latvia;Germany;United Kingdom

EUCTR2016-004138-12-GB
(EUCTR)

30/10/2017

17/07/2017

Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.

Astellas Pharma Europe B.V.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: no

163

Phase 2

Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom

EUCTR2016-004138-12-NL
(EUCTR)

23/10/2017

24/07/2017

Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.

Astellas Pharma Europe B.V.

NULL

Not Recruiting

Female: yes
Male: no

163

Phase 2

Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Latvia;Germany;Netherlands;United Kingdom

NCT03282318
(ClinicalTrials.gov)

September 28, 2017

12/9/2017

A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis

Bladder Pain Syndrome;Interstitial Cystitis

Drug: ASP6294;Drug: Placebo

Astellas Pharma Europe B.V.

NULL

Completed

18 Years

N/A

Female

119

Phase 2

Belgium;Czechia;Germany;Hungary;Latvia;Netherlands;Poland;Russian Federation;Spain;United Kingdom

EUCTR2016-004138-12-PL
(EUCTR)

27/09/2017

19/07/2017

Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.

Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC)
MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]

Product Name: ASP6294
INN or Proposed INN: Not applicable
Other descriptive name: ASP6294

Astellas Pharma Europe B.V.

NULL

Not Recruiting

Female: yes
Male: no

163

Phase 2

Hungary;Czech Republic;Belgium;Spain;Poland;Russian Federation;Netherlands;Latvia;Germany;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2016-004138-12-DE
(EUCTR)

26/09/2017

10/07/2017

Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.

Astellas Pharma Europe B.V.

NULL

Not Recruiting

Female: yes
Male: no

163

Phase 2

Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom

EUCTR2016-004138-12-ES
(EUCTR)

18/09/2017

Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.

Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC)
MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]

Product Name: ASP6294
INN or Proposed INN: Not applicable
Other descriptive name: ASP6294

Astellas Pharma Europe B.V.

NULL

Not Recruiting

Female: yes
Male: no

163

Phase 2

Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom

EUCTR2016-004138-12-HU
(EUCTR)

14/09/2017

12/07/2017

Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.

Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC)
MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]

Product Name: ASP6294
INN or Proposed INN: Not applicable
Other descriptive name: ASP6294

Astellas Pharma Europe B.V.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: no

163

Phase 2

Czech Republic;Hungary;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom

EUCTR2016-004138-12-CZ
(EUCTR)

30/08/2017

13/07/2017

Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.

Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC)
MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]

Product Name: ASP6294
INN or Proposed INN: Not applicable
Other descriptive name: ASP6294

Astellas Pharma Europe B.V.

NULL

Not Recruiting

Female: yes
Male: no

163

Phase 2

Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Latvia;Germany;United Kingdom

EUCTR2016-004138-12-LV
(EUCTR)

04/08/2017

25/07/2017

Study of the effect of ASP6294 for the treatment of Bladder Pain Syndrome/Interstitial Cystitis in female subjects.

Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC)
MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419 ;Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]

Astellas Pharma Europe B.V.

NULL

Not Recruiting

Female: yes
Male: no

163

Phase 2

Hungary;Czech Republic;Poland;Belgium;Spain;Russian Federation;Netherlands;Germany;Latvia;United Kingdom